Brief: Vertex Pharmaceuticals VERTEX PHARMACEUTICALS Q3 ADJUSTED EPS USD 4.8 VS. IBES ESTIMATE USD 4.56
03/11/2025 21:02
Nov 03 (Reuters) - Vertex Pharmaceuticals Q3 adjusted net income USD 1,082.9 million vs. IBES estimate USD 1,190 million. VERTEX PHARMACEUTICALS Q3 REVENUE USD 3,080 MILLION VS. IBES ESTIMATE USD 3,053 MILLION VERTEX PHARMACEUTICALS Q3 EPS USD 4.2 VERTEX PHARMACEUTICALS OUTLOOK FY REVENUE USD 11,900-12,000 MILLION
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31